Dissection of the VI cervical lymph collector for papillary thyroid cancer

Abstract

Objective. To assess the expediency and necessity of implementing the dissection of the central cervical lymph nodes (group VI) in patients with papillary thyroid cancer.

Materials and methods. The results of preoperative examination, surgical treatment and its follow-up were evaluated in 210 patients, who along with thyreoidectomy, underwent dissection of the central cervical lymph nodes (group VI).

Results. It was established that for papillary thyroid cancer, a high frequency of cervical lymph node metastasis is typical. During the preoperative examination, (US and cytological study), metastases were detected in 23.5 % of patients, and while pathomorphological study of the removed central neck cellular tissue – in 47.4 % more. Therefore, preventive dissection of the central cervical lymph nodes (VI group) is worthwhile.

Though expansion of the volume of operations in patients with papillary thyroid cancer at the expense of dissecting the central cervical lymph nodes in addition to the thyroid gland, leads to insignificant elevation of the number of complications but in the remote period (3–5 years), volume expansion of operations has no negative impact on the indicators of physical and psychical components of the life quality.

Conclusions. The obtained objective information regarding the presence or absence of metastatic lesion of the cervical lymph nodes permits to ground the process staging in papillary thyroid cancer and form treatment tactics.

Keywords

thyroid gland / papillary cancer / metastases / central lymphodissection

References

[1] Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer 2021; 5.

[2] Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021; Apr 5.

[3] Islami F., Ward E.M., Sung H., Cronin K.A., Tangka F., Sherman R.L., Zhao J., Anderson R.N., Henley S.J., Yabroff K.R., Jemal A., Benard V.B. Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics, JNCI: Journal of the National Cancer Institute 2021; 113 (12): 1648–1669.

[4] Farhad Islami, Elizabeth M Ward, Hyuna Sung, Kathleen A Cronin, Florence K L Tangka, Recinda L Sherman, Jingxuan Zhao, Robert N Anderson, S Jane Henley, K Robin Yabroff, Ahmedin Jemal, Vicki B Benard. Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics, JNCI: Journal of the National Cancer Institute 2021; 113 (12): 1648–1669.

[5] Lim H., Devesa S.S., Sosa J.A., Check D., Kitahara C.M. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974–2013. JAMA 2017; 317 (13): 1338–1348.

[6] James B.C., Mitchell J.M., Jeon H.D., Vasilottos N., Grogan R.H., Aschebrook-Kilfoy B. An update in international trends in incidence rates of thyroid cancer, 1973–2007. Cancer Causes Control 2018; 29 (4–5): 465–473.

[7] Kropotov M.A., Grachev E.A., Yakovleva L.P., Khodos A.V., Tigrov M.S. Central cervical lymphodissection in surgical treatment of papillary thyroid cancer. Malignant tumors 2019; 9 (2): 27–34 (in Russian).

[8] Кропотов М.А., Гривачев Е.А., Яковлева Л.П., Ходос А.В., Тигров М.С. Центральная шейная лимфодиссекция при хирургическом лечении папиллярного рака щитовидной железы. Злокачественные опухоли 2019; 9 (2): 27–34.

[9] Grani G., Sponziello M., Pecce V., Ramundo V., Durante C. Contemporary Thyroid Nodule Evaluation and Management. J Clin Endocrinol Metab. 2020; 105 (9): 2869–2883.

[10] Kumbhar S.S., O'Malley R.B., Robinson T.J., Maximin S., Lalwani N., Byrd D.R., Wang C.L. Why Thyroid Surgeons Are Frustrated with Radiologists: Lessons Learned from Pre- and Postoperative US. Radiographics 2016; 36 (7): 2141–2153.

[11] Di Meo G., Prete F.P., De Luca G.M., Pasculli A., Sgaramella L.I., Minerva F., Logoluso F.A., Calculli G., Gurrado A., Testini M. The Value of Intraoperative Ultrasound in Selective Lateral Cervical Neck Lymphadenectomy for Papillary Thyroid Cancer: A Prospective Pilot Study. Cancers (Basel) 2021; 13 (11): 2737.

[12] Fisenko E.P., Sencha A.N., Katrich A.N., Sych Yu.P., Tsvetkova N.V., Borsukov A.V., Kostromina E.V. Оn the need to introduce the TI-RADS classification in Russia. Clinical and experimental thyroidology 2019; 15 (2): 55–63 (in Russian).

[13] Zhong M., Zhang Z., Xiao Y., He Y., Chen Y., Huang W.J., Lu L. The Predictive Value of ACR TI-RADS Classification for Central Lymph Node Metastasis of Papillary Thyroid Carcinoma: A Retrospective Study. Int J Endocrinol. 2022; 2022: 4412725.

[14] Bel’tsevich D.G., Mudunov A.M., Vanushko V.E., Rumiantsev P.O., Mel’nichenko G.A., Kuznetsov N.S., Podvyaznikov S.O., Alymov Y.V., Poliakov A.P., Fadeev V.V., Bolotin M.V., Sevriukov F.E., Krylov V.V., Fedenko A.A., Bolotina L.V., Zharov A.A., Falaleeva N.A., Filonenko E.V. Differentiated thyroid cancer. Journal of Modern Oncology 2020; 22 (4): 30–44 (in Russian).

[15] Бельцевич Д.Г., Мудунов А.М., Ванушко В.Э., Румянцев П.О., Мельниченко Г.А., Кузнецов Н.С., Подвязников С.О., Алымов Ю.В., Поляков А.П., Фадеев В.В., Болотин М.В., Севрюков Ф.Е., Крылов В.В., Феденко А.А., Болотина Л.В., Жаров А.А., Фалалеева Н.А., Филоненко Е.В., Невольских А.А., Иванов С.А., Хайлова Ж.В., Геворкян Т.Г. Дифференцированный рак щитовидной железы. Современная онкология 2020; 22 (4): 30–44.

[16] Vertyankin S.V., Duboshina T.B., Askerov M.R., Grekov V.V., Tarlykova I.A. Study on life quality in the patients with benign thyroid pathology prior to and after surgery. Tauride medico-biological Bulletin 2017; 20 (3–2): 60–67 (in Russian).

[17] Вертянкин С.В., Дубошина Т.Б., Аскеров М.Р., Греков В.В., Турлыкова И.А. Изучение качества жизни у больных с после операции доброкачественной тиреоидной патологией до и после операции. Таврический медико-биологический вестник 2017; 20 (3–2): 60–67.

RIGHTS & PERMISSIONS

Eco-Vector